John G Ullman & Associates Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 900 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. John G Ullman & Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $442,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Korea Investment CORP increased its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth $140,000. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares in the last quarter. Wendell David Associates Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter worth $204,000. Finally, Welch & Forbes LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth $211,000. Institutional investors and hedge funds own 67.16% of the company’s stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at 467.98 on Friday. The stock has a 50 day moving average price of $489.51 and a 200-day moving average price of $430.92. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55. The firm has a market capitalization of $49.62 billion, a P/E ratio of 46.95 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.82 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current fiscal year.
A number of research firms have recently issued reports on REGN. UBS AG set a $489.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research report on Monday, May 15th. Piper Jaffray Companies raised their price objective on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research report on Tuesday, June 20th. Leerink Swann reissued an “outperform” rating and set a $580.00 price target (up from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $472.00 price target (up from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $495.59.
In other news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the transaction, the senior vice president now directly owns 9,193 shares in the company, valued at $4,894,537.06. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Sanofi acquired 136,050 shares of the company’s stock in a transaction dated Friday, June 2nd. The shares were acquired at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 84,404 shares of company stock worth $40,303,792. Insiders own 10.40% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
